11:16 PM
Login form
Entries archive

Africa Live News

Main » 2014 » April » 7 » Cell Signaling Technology, Inc. Announces PD-L1 Antibody, Important to Cancer Immunotherapy Research
11:17 AM
Cell Signaling Technology, Inc. Announces PD-L1 Antibody, Important to Cancer Immunotherapy Research

ME Newswire / Businesswire

DANVERS, Mass - Sunday, April 6th 2014

Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today that it has introduced a highly specific PD-L1 rabbit monoclonal antibody (mAb). Recent reports have shown PD-L1 to be up-regulated on the surface of tumor cells, implicating this protein as one of the factors that allows tumors to evade the immune system. CST’s PD-L1 Rabbit mAb is an important addition for researchers studying tumor immunology and potential approaches to immunotherapy for melanoma, lung, ovarian, renal, prostate, and other cancers. Clinical researchers are evaluating antibodies to PD-L1 as potential cancer biotherapeutics (Brahmer, J.R., et al. (2012) New Engl J Med 366,2455-65).

PD-L1 Antibody Applications

PD-L1 interacts with PD-1, a surface receptor on activated T cells. PD-L1 binding leads to inhibition of T cell activity. Immunohistochemistry (IHC) is an important application for studying the role of PD-L1 in human and/or mouse xenograft samples, and CST’s PD-L1 (E1L3N) XP® Rabbit mAb #13684 has been validated for recognition of human PD-L1 in IHC as well as for immunofluorescence, flow cytometry, western blot, and immunoprecipitation*. The high specificity and sensitivity of this antibody are supported by western blot detection of a single band at the appropriate molecular weight and by the IHC detection of endogenous levels of PD-L1 in tumor cells (image).

CST is known for the development of highly specific, thoroughly validated antibodies to targets relevant to translational research, including cellular checkpoints and cancer signaling. Past efforts by CST’s Cancer Research Group have focused on unraveling the signaling networks that underlie various cancers and include the identification of the EML4-ALK fusion, which has been reported in a subset of patients with breast, colon and non-small cell lung cancer (NSCLC). The impacts of EML4-ALK in NSCLC span from research through diagnosis and therapy (Patents 8,486,645, 8,481,279, 8,377,642, 8,288,102, 8,232,060, 8,168,383, and 7,700,339).

About CST

Founded by research scientists in 1999, CST is a private, family-owned company with over 400 employees worldwide. Active in the field of applied systems biology research, particularly as it relates to cancer, CST understands the importance of using antibodies with high levels of specificity and lot-to-lot consistency. We produce all of our antibodies in house, and perform painstaking validations for multiple applications. Technical support is provided by the same CST scientists who produce our antibodies, helping customers design experiments, troubleshoot, and achieve reliable results. CST is certified by BSI to be compliant with ISO 9001:2008 for the design, development, and production of monoclonal antibodies.

* For Research Use Only. Not For Use in Diagnostic Procedures.

Cell Signaling Technology®, CST™, and XP® are trademarks of Cell Signaling Technology.

Photos/Multimedia Gallery Available:


Cell Signaling Technology, Inc.

David M. Freeman, 978-867-8865

VP of Global Marketing






Views: 240 | Added by: africa-live | Rating: 0.0/0
Total comments: 0